Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 0.38 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 2/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481347 | 0.88 | CYSLTR1 (0.52) | GRM2CYSLTR1CYSLTR2 | |
| SCHEMBL5200800 | 0.85 | CYSLTR1 (0.41) | GRM2CYSLTR1CYSLTR2CTSD | |
| SCHEMBL481362 | 0.80 | GRM2 (0.54) | GRM2CYSLTR1CYSLTR2CTSD | |
| SCHEMBL481148 | 0.74 | CYSLTR1 (0.56) | GRM2CYSLTR1CYSLTR2 | |
| SCHEMBL481013 | 0.74 | CYSLTR1 (0.55) | GRM2CYSLTR1CYSLTR2 | |
| SCHEMBL5200758 | 0.72 | CYSLTR1 (0.44) | GRM2CYSLTR1CYSLTR2 | |
| SCHEMBL5199133 | 0.72 | CYSLTR1 (0.43) | GRM2CYSLTR1CYSLTR2 | |
| SCHEMBL481036 | 0.71 | CYSLTR1 (0.35) | GRM2CYSLTR1CYSLTR2CTSD | |
| SCHEMBL481105 | 0.70 | CYSLTR1 (0.63) | GRM2CYSLTR1CYSLTR2 | |
| SCHEMBL3095440 | 0.69 | CYSLTR1 (0.42) | GRM2CYSLTR1CYSLTR2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817301-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006057870-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |